Fig. 1 (a) Thermal melting curves for poly(dA)·[poly(dT)]2 triplex DNA in the absence and presence of amide ligands 2b, 2e–g (DNA: 50 µM in base triads;
ligands: 25 µM. Competition equilibrium dialysis data for compounds (b) 1b and (c) 2b; for a full description of the nucleic acid structures used, see reference
11.
triplex stabilisation was dependent upon the nature of the basic
side-chains with the bulkier and more hydrophobic groups
In conclusion, substituted biarylpyrimidines present an
intriguing platform for the design of ligands to recognise high-
order nucleic acid structures. Furthermore, a structural switch
has been devised which alters binding preference for triplex or
tetraplex DNA forms. No compounds examined showed
appreciable cytotoxicity in a range of human tumour cell lines
(IC50 4 100 µM), consistent with only weak affinity for duplex-
form DNA. As expected for tetraplex-binding ligands, moderate
inhibition of human telomerase was found (IC50 4 10 µM).§
1
being more effective (e.g. piperidinyl, 1f: DTm = 17.4 °C;
1
diethylamino, 1b: DTm = 20.2 °C) although no correlation
with the pKa of the basic amino group (1a < 1e < 1b) was
apparent.
Minor structural alteration to the amides 2, resulted in a
significantly different pattern of DTm values. The simple
dialkylamino compounds, e.g. 2a, induced a small stabilisation
2
of poly(dA)·poly(dT) duplex (DTm 5 8.1 °C) with little effect
1
on triplex melting (mostly DTm 5 1 °C). Spectrophotometric
titration of dimethylamino compounds 1a or 2a with poly-
(dA)·poly(dT) duplex or poly(dA)·[poly(dT)]2 triplex con-
firmed the lack of interaction of amide 2a with the three-
stranded DNA structure: hypochromicity and sharp isosbestic
points were observed in all titrations except in the case of amide
2a with triplex-form DNA. Remarkable structure-selective
differences were seen for the amide ligands bearing saturated
heterocyclic side chains (2e–g), see Figure 1 panel (a). Ligands
2f,g showed closely similar effects: a marked stabilisation of
Notes and references
‡ Satisfactory spectroscopic and analytical data were obtained for all
compounds. See ESI.†
§ This work was supported by the EPSRC (grant GR/N 37605 to RTW and
TCJ), Yorkshire Cancer Research (to TCJ), National Cancer Institute (grant
CA35635 to JBC) and an EPSRC CASE studentship with Enact Pharma plc.
Mass spectra were obtained from the EPSRC National Mass Spectrometry
Service Centre, University of Wales, Swansea.
2
poly(dA)·poly(dT) duplex (DTm ≈ 14 °C) accompanied by a
1 T. C. Jenkins, Current Med. Chem., 2000, 7, 99–115; H. Arthanari and
P. H. Bolton, Chem. Biol., 2001, 8, 221–230; J.-L. Mergny and C.
Hélène, Nature Med., 1998, 4, 1366–1367; C. L. Grand, H. Han, R. M.
Munoz, S. Weitman, D. D. Von Hoff, L. H. Hurley and D. J. Bearss,
Mol. Cancer Ther., 2002, 1, 565–573.
2 T. de Lange and T. Jacks, Cell, 1999, 96, 273–275; E. H. Blackburn,
Nature, 1991, 350, 569–573; S. S. Smith, A. Laayoun, R. G. Lingeman,
D. J. Baker and J. Ridley, J. Mol. Biol., 1994, 243, 143–150; K. Usdin
and K. J. Woodford, Nucleic Acids Res., 1995, 23, 4202–4209; A.
Siddiqui-Jain, C. L. Grand, D. J. Bearss and L. H. Hurley, Proc. Nat.
Acad. Sci. USA, 2002, 99, 11593–11598.
3 W. D. Wilson, L. Strekowski, F. A. Tanious, R. A. Watson, J. L.
Mokrosz, A. Strekowska, G. D. Webster and S. Neidle, J. Am. Chem.
Soc., 1988, 110, 8292–8299.
4 Y. Wang and D. J. Patel, Structure, 1993, 1, 263–282.
5 A. N. Lane and T. C. Jenkins, Current Org. Chem., 2001, 5, 845–870;
V. N. Soyfer and V. N. Potaman, Triple-helical Nucleic Acids, Springer-
Verlag, 1996.
6 H. Bredereck, R. Gompper and G. Morlock, Chem. Ber., 1957, 90,
942–951; C. G. Herbert, R. G. Bass, K. A. Watson and J. W. Connell,
Macromol., 1996, 29, 7709–7716.
7 D.-F. Shi, R. T. Wheelhouse, D. Sun and L. H. Hurley, J. Med. Chem.,
2001, 44, 4509–4523; D.-F. Shi and R. T. Wheelhouse, Tetrahedron
Lett., 2002, 43, 9341–9342.
8 E. Boucher, M. Simard and J. D. Wuest, J. Org. Chem., 1995, 60,
1408–1412.
9 L. Testaferri, M. Tiecco, M. Tingoli and D. Chianelli, Synthesis
Commun., 1983, 751–755; L. Testaferri, M. Tingoli and M. Tiecco,
Tetrahedron Lett., 1980, 21, 3099–3100.
1
specific destabilisation of the triplex structure (DTm ≈ 25 °C)
that preserved the shape of the biphasic melting curve. An
intermediate effect was observed for the morpholino derivative
2e. The structural basis for these differential behaviours and the
selective destabilisation of triplex DNA is uncertain and the
subject of continuing investigations.
The structure preferences and relative binding affinities were
further investigated by competitive equilibrium dialysis.11
Figure 1 panels (b) and (c) show data obtained for compounds
1b and 2b. These results broadly confirmed that neither ligand
family had a strong affinity for any nucleic acid duplex; as
anticipated, preferential interactions with high-order structures
were evident. In agreement with the thermal and spectrophoto-
metric data, thioether 1b showed a strong preference for triplex
DNA (27-fold greater than for the natural duplex, CT DNA).
Significantly less ligand bound to triplex RNA, indicating that
at least part of the bound ligand (probably the pendant side
chains) must align in the grooves of the DNA triplex—an
accommodation thwarted by the 2A-hydroxyl groups in the all-
RNA structure.5 In contrast, the amide 2b bound more strongly
with tetraplex DNA structures (Figure 1, panel (c)) but was less
discriminating in its recognition profile. Uncharged compounds
1c,d and 2c,d showed greatly reduced affinity for nucleic acids
but the structure preferences generally resembled those of their
dimethylamino counterparts. In both series, variation of the
simple dialkyamino groups only influenced binding affinity
(e.g. Z = NMe2 > NEt2) whilst the overall selectivity was
unaffected. However, compounds bearing saturated hetero-
cyclic side-chains, showed distinctly different patterns of
binding preferences, in agreement with their anomalous thermal
melting behaviour.
10 A. W. McConnaughie and T. C. Jenkins, J. Med. Chem., 1995, 38,
3488–3501; I. Haq, J. E. Ladbury, B. Z. Chowdhry and T. C. Jenkins, J.
Am. Chem. Soc., 1996, 118, 10693–10701.
11 J. S. Ren and J. B. Chaires, Biochemistry, 1999, 38, 16067–16075; J. S.
Ren and J. B. Chaires, J. Am. Chem. Soc., 2000, 122, 424–425; J. S. Ren
and J. B. Chaires, Meth. Enzymol., 2001, 340, 99–108.
CHEM. COMMUN., 2003, 1160–1161
1161